Top line data from the Phase IIb trial evaluating PeproStat™ is now expected in Q4 2017, earlier than the original Q1 2018 due to reaching recruitment mid-point ahead of schedule. This highlights Ergomed’s ability to recruit patients successfully and undertake trials efficiently. PeproStat™ offers a differentiated approach to current products in the haemostat market in that it is manufactured from blood-free components and is formulated in a ready-to-use solution. We reiterate our highly positiv ....
21 Jun 2017
N+1 Singer - Ergomed - Top line PeproStat™ Phase IIb data now expected in Q4 2017
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Ergomed - Top line PeproStat™ Phase IIb data now expected in Q4 2017
- Published:
21 Jun 2017 -
Author:
Sheena Berry -
Pages:
3
Top line data from the Phase IIb trial evaluating PeproStat™ is now expected in Q4 2017, earlier than the original Q1 2018 due to reaching recruitment mid-point ahead of schedule. This highlights Ergomed’s ability to recruit patients successfully and undertake trials efficiently. PeproStat™ offers a differentiated approach to current products in the haemostat market in that it is manufactured from blood-free components and is formulated in a ready-to-use solution. We reiterate our highly positiv ....